Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.

Rosenthal S, Chen R, Hadler S.

Arch Pediatr Adolesc Med. 1996 May;150(5):457-60.

PMID:
8620224
3.

A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.

Zangwill KM, Eriksen E, Lee M, Lee J, Marcy SM, Friedland LR, Weston W, Howe B, Ward JI.

Pediatrics. 2008 Dec;122(6):e1179-85. doi: 10.1542/peds.2008-1977.

PMID:
19047220
4.
6.

Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.

Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, Blackwelder WC, Jansen DL, Meade BD.

Pediatrics. 2000 Jan;105(1):e11.

PMID:
10617748
7.

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD.

Pediatrics. 1997 Nov;100(5):772-88.

PMID:
9346976
8.

Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.

Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, Meekison W, Eastwood BJ.

Pediatr Infect Dis J. 1999 Sep;18(9):772-9.

PMID:
10493336
9.
11.
12.

[Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].

van der Maas NA, David S, Kemmeren JM, Vermeer-de Bondt PE.

Ned Tijdschr Geneeskd. 2007 Dec 8;151(49):2732-7. Dutch.

PMID:
18225797
13.

Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.

Auerbach BS, Lake AM, Wilson ME, Willingham FF, Shematek J, Moulton L, Deforest A, Halsey NA.

Biologicals. 1998 Jun;26(2):145-53.

PMID:
9811522
14.

Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.

Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR.

Arch Pediatr Adolesc Med. 2000 Aug;154(8):797-803.

PMID:
10922276
15.

Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.

Nolan T, Bernstein H, Blatter MM, Bromberg K, Guerra F, Kennedy W, Pichichero M, Senders SD, Trofa A, Collard A, Sullivan DC, Descamps D.

Pediatrics. 2006 Sep;118(3):e602-9.

PMID:
16950952
16.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov..

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
18.

Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.

Halperin SA, Scheifele D, Mills E, Guasparini R, Humphreys G, Barreto L, Smith B.

Vaccine. 2003 Jun 2;21(19-20):2298-306.

PMID:
12744860
20.

Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.

Feldman S, Perry CS, Andrew M, Jones L, Moffitt JE, Lamb D, Meschievitz C.

South Med J. 1993 Mar;86(3):269-75, 284.

PMID:
8451663

Supplemental Content

Support Center